| Nov 13 |
Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear
|
| Nov 13 |
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
|
| Nov 13 |
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
|
| Nov 12 |
GILD or VRTX: Which Is the Better Value Stock Right Now?
|
| Nov 12 |
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
|
| Nov 11 |
Gilead Sciences: Approaching Overvalued
|
| Nov 10 |
3 Spectacular High-Yield Dividend Stocks to Buy in November
|
| Nov 8 |
Gilead Sciences: Finally Some Real Momentum
|
| Nov 8 |
Gilead Sciences to Present at Upcoming Investor Engagements
|
| Nov 8 |
Gilead Sciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
